MedTrace Logo

Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

NCT03632759 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-01-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Liraglutide

Participants will receive subcutaneous (SC) liraglutide for 8 weeks

DRUG

Golimumab

Participants will receive subcutaneous (SC) golimumab for 8 weeks

Sponsors & Collaborators

  • Juvenile Diabetes Research Foundation

    collaborator OTHER

  • Carla Greenbaum, MD

    lead OTHER

Principal Investigators

  • Carla Greenbaum, MD · Benaroya Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-15
Primary Completion
2021-11-09
Completion
2021-11-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03632759 on ClinicalTrials.gov